drugset / Trial / NCT04990388
Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)
RandomizedSequentialQuadruple-blindTreatment
Summary
The primary objective of the study is to evaluate the safety of UX053 in adults with Glycogen Storage Disease Type III (GSD III).
Timeline
- Start
- 2021-10-18
- Primary completion
- 2023-03-20
- Completion
- 2023-03-20
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision not related to safety concerns”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UX053 | Unknown | — | Intravenous |
| Background | Acetaminophen | Small molecule | — | Oral |
| Background | Cetirizine | Other / unclassified | — | Oral |
| Background | Famotidine | Other / unclassified | — | Oral |
| Background | Ibuprofen | Small molecule | — | Oral |